Multiple Myeloma

The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, Kahler's Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management.

Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the increased number of therapeutic options to choose from, the clinician is better placed to offer effective therapy but at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the treatment options today and in the future. Multiple Myeloma provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data and offers evidence-based recommendations.

About the Series:

Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

Features of Emerging Cancer Therapeutics include:

Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics
In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics
Issues edited by an authority in specific subject area
Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience
Emphasizes multidisciplinary approaches to research and practice
- return to top -

Contents
Foreword, Preface, Contributors, The Etiology and Pathophysiology of Multiple Myeloma, Loredana Santo and Noopur Raje, Genetic Abnormalities in Multiple Myeloma, Wee J. Chng, Monoclonal Gammopathy of Undetermined Significance, Sumit Madan and S.Vincent Rajkumar, Smoldering Multiple Myeloma, John A. Lust and Kathleen A. Donovan, Laboratory Evaluation and Diagnosis of Monoclonal Gammopathies, Myo Htut and Amrita Krishnan, Prognostic Factors and Risk Stratification in Myeloma, Prashant Kapoor and Shaji Kumar, Initial Treatment of Multiple Myeloma in Transplant-Eligible Patients, Jacob Laubach, Robert Schlossman, Constantine Mitsiades, Kenneth Anderson, and , Paul Richardson, Current Trends in Hematopoietic Stem Cell Transplantation for Multiple Myeloma, Parameswaran Hari and Ayman Saad, Treatment of Myeloma in Transplant-Ineligible Patients, Francesca Gay, Stefania Oliva, and Antonio Palumbo, Relapsed and Refractory Multiple Myeloma, Taiga Nishihori and Melissa Alsina, Management of Treatment Complications and Supportive Care, Francis Buadi, Index
- return to top -

About the Guest Editors
Shaji Kumar, MD
Shaji Kumar, MD, Associate Professor of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota

Jame Abraham, MD, FACP

Jame Abraham, MD, FACP, Bonnie Wells Wilson Distingushed Professor and Eminent Scholar, Chief, Section of Hematology-Oncology, and Medical Director, Mary Babb Randolph Cancer Center, West Virginia University.